This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $295,153.00 to Safebeat RX Inc. to develop a novel, smartwatch-enabled technology that allows low-risk atrial fibrillation patients to safely initiate heart rhythm medications at home. The technology uses machine learning to analyze ECG data from patients' smartwatches and sends the data to physicians, who can then adjust drug dosages as needed. This aims to address the current requirement for a 3-day hospitalization period to monitor patients starting certain antiarrhythmic medications. The award period runs from September 17, 2024 to February 28, 2025.
Generated 3/4/25, 7:13 AM